NanoViricides, Inc. Common Stock (NY:NNVC)

1.385 -0.065 (-4.48%)

Delayed Quote Updated: 2:06 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

NanoViricides to Present at the Biotech Showcase in San Fransisco

January 04, 2024

Via ACCESSWIRE

Is This Ticker That InvestorsObserver Expects To Soar By More Than 350% Next Year On Your Watchlist?

December 01, 2023

--News Direct--

Via News Direct

Topics Death

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

November 28, 2023

Via ACCESSWIRE

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

November 15, 2023

Via ACCESSWIRE

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

November 14, 2023

Via ACCESSWIRE

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV

October 16, 2023

Via ACCESSWIRE

NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET

October 12, 2023

Via ACCESSWIRE

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗

October 02, 2023

Read the latest report on NanoViricides here

Via Benzinga

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗

September 26, 2023

Read the latest report on NanoViricides here

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 22, 2023

Via Benzinga

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides

August 21, 2023

Via ACCESSWIRE

SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? ↗

July 18, 2023

Read the latest report on NanoViricides here.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 11, 2023

Via Benzinga

Why Are NanoViricides Shares Gaining Today ↗

July 11, 2023

NanoViricides Inc (NYSE: NNVC) shares are trading higher after the company reported preclinical data from an antiviral clinical drug candidate for

Via Benzinga

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?

July 11, 2023

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?

Via News Direct

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?

July 11, 2023

By David Willey, Benzinga

Via TheNewswire.com

Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket ↗

July 11, 2023

Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday.

Via Benzinga

Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides

July 11, 2023

Via ACCESSWIRE

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target? ↗

July 10, 2023

Read the latest report on NanoViricides here.

Via Benzinga

NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment

July 06, 2023

NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment

Via News Direct

NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment

July 06, 2023

By David Willey, Benzinga

Via TheNewswire.com

Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

July 06, 2023

Via ACCESSWIRE

NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment ↗

July 05, 2023

Read the latest report on NanoViricides here.

Via Benzinga

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

June 29, 2023

Via ACCESSWIRE

The 7 Most Promising Penny Stocks to Buy in June ↗

June 07, 2023

These top penny stocks for June look to have legitimate catalysts that can certainly send share prices higher.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 02, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 01, 2023

Via Benzinga

NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET

May 31, 2023

Via ACCESSWIRE

NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin

May 16, 2023

Via ACCESSWIRE

TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference

May 04, 2023

Via Investor Brand Network

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.